These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 30922805

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
    Wang R, Smyth LM, Iyengar N, Chandarlapaty S, Modi S, Jochelson M, Patil S, Norton L, Hudis CA, Dang CT.
    Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
    Perez EA, López-Vega JM, Petit T, Zamagni C, Easton V, Kamber J, Restuccia E, Andersson M.
    Breast Cancer Res; 2016 Dec 13; 18(1):126. PubMed ID: 27955684
    [Abstract] [Full Text] [Related]

  • 6. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
    Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S.
    Trials; 2020 May 07; 21(1):391. PubMed ID: 32381018
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.
    Kuemmel S, Harper-Wynne C, Park YH, Franke F, de Laurentiis M, Schumacher-Wulf E, Eiger D, Heeson S, Cardona A, Özyilkan Ö, Morales-Vàsquez F, Metcalfe C, Hafner M, Restuccia E, O'Shaughnessy J.
    BMC Cancer; 2024 May 24; 24(1):641. PubMed ID: 38789924
    [Abstract] [Full Text] [Related]

  • 9. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H, Tryfonidis K, Dal Lago L, Vuylsteke P, Curigliano G, Waters S, Brouwers B, Altintas S, Touati N, Cardoso F, Brain E.
    Lancet Oncol; 2018 Mar 24; 19(3):323-336. PubMed ID: 29433963
    [Abstract] [Full Text] [Related]

  • 10. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
    Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J, CLEOPATRA study group.
    Lancet Oncol; 2020 Apr 24; 21(4):519-530. PubMed ID: 32171426
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF, Manrique C, Pun S, Liu JE, Mara E, Fleisher M, Patil S, Jones LW, Steingart RM, Hudis CA, Dang CT.
    Oncologist; 2016 Apr 24; 21(4):418-24. PubMed ID: 26984450
    [Abstract] [Full Text] [Related]

  • 13. Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
    Kuemmel S, Tondini CA, Abraham J, Nowecki Z, Itrych B, Hitre E, Karaszewska B, Juárez-Ramiro A, Morales-Vásquez F, Pérez-García JM, Cardona-Huerta S, Monturus E, Sequi M, Restuccia E, Benyunes M, Martín M.
    Breast Cancer Res Treat; 2021 Jun 24; 187(2):467-476. PubMed ID: 33748921
    [Abstract] [Full Text] [Related]

  • 14. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D.
    Lancet Oncol; 2018 Jan 24; 19(1):115-126. PubMed ID: 29175149
    [Abstract] [Full Text] [Related]

  • 15. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
    Láng I, Bell R, Feng FY, Lopez RI, Jassem J, Semiglazov V, Al-Sakaff N, Heinzmann D, Chang J.
    Clin Oncol (R Coll Radiol); 2014 Feb 24; 26(2):81-9. PubMed ID: 24051172
    [Abstract] [Full Text] [Related]

  • 16. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
    Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi GV, Magazzù D, McNally V, Douthwaite H, Ross G, Valagussa P.
    Lancet Oncol; 2016 Jun 24; 17(6):791-800. PubMed ID: 27179402
    [Abstract] [Full Text] [Related]

  • 17. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.
    Smyth LM, Iyengar NM, Chen MF, Popper SM, Patil S, Wasserheit-Lieblich C, Argolo DF, Singh JC, Chandarlapaty S, Sugarman SM, Comen EA, Drullinsky PR, Traina TA, Troso-Sandoval T, Baselga J, Norton L, Hudis CA, Dang CT.
    Breast Cancer Res Treat; 2016 Jul 24; 158(1):91-97. PubMed ID: 27306421
    [Abstract] [Full Text] [Related]

  • 18. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
    Jhaveri K, Wang R, Teplinsky E, Chandarlapaty S, Solit D, Cadoo K, Speyer J, D'Andrea G, Adams S, Patil S, Haque S, O'Neill T, Friedman K, Esteva FJ, Hudis C, Modi S.
    Breast Cancer Res; 2017 Aug 02; 19(1):89. PubMed ID: 28764748
    [Abstract] [Full Text] [Related]

  • 19. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
    Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, CLEOPATRA Study Group.
    N Engl J Med; 2012 Jan 12; 366(2):109-19. PubMed ID: 22149875
    [Abstract] [Full Text] [Related]

  • 20. Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.
    Inoue K, Ninomiya J, Saito T, Okubo K, Nakakuma T, Yamada H, Kimizuka K, Higuchi T, SBCCSG-36 investigators.
    Invest New Drugs; 2019 Jun 12; 37(3):538-547. PubMed ID: 30848403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.